Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

TriSalus Life Sciences (TLSI) Payables (2021 - 2026)

TriSalus Life Sciences has reported Payables over the past 6 years, most recently at $4.2 million for Q1 2026.

  • For Q1 2026, Payables rose 50.82% year-over-year to $4.2 million; the TTM value through Mar 2026 reached $4.2 million, up 50.82%, while the annual FY2025 figure was $3.0 million, 32.01% up from the prior year.
  • Payables for Q1 2026 was $4.2 million at TriSalus Life Sciences, up from $3.0 million in the prior quarter.
  • Over five years, Payables peaked at $5.9 million in Q4 2022 and troughed at $1.4 million in Q3 2024.
  • A 5-year average of $2.8 million and a median of $2.3 million in 2024 define the central range for Payables.
  • Biggest five-year swings in Payables: surged 267.82% in 2022 and later tumbled 53.43% in 2024.
  • Year by year, Payables stood at $5.9 million in 2022, then crashed by 42.44% to $3.4 million in 2023, then crashed by 32.94% to $2.3 million in 2024, then soared by 32.01% to $3.0 million in 2025, then skyrocketed by 40.97% to $4.2 million in 2026.
  • Business Quant data shows Payables for TLSI at $4.2 million in Q1 2026, $3.0 million in Q4 2025, and $3.8 million in Q3 2025.